Clinical trial
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter…
NCT00267930 · Advanz Pharma, Industry · Completed
Key facts
| NCT number | NCT00267930 |
|---|---|
| Title | Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence |
| Official title | A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF |
| Lead sponsor | Advanz Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Vernakalant (oral), Placebo comparator |
| Enrollment | 221 |
| Start date | Dec 1, 2005 |
| Completion | Aug 1, 2006 |
| First posted | Dec 22, 2005 |
| Last update posted | Dec 18, 2008 |
| Countries | Canada, Denmark, Netherlands, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: